Elevance Health Inc.
NYSE:ELVMedical - Healthcare Plans
-$3.45 today
- Market cap
- $86.60B
- Beta
- 0.68
- P/E (TTM)
- 16.3
- EPS (TTM)
- $23.78
- Dividend yield
- 1.77%
Volume 1.91M
Average 1.68M
ELV Interest Expense
Cost of servicing the company's debt during the period.
Elevance Health Inc.NYSE: ELV
Interest Expense · Q3 FY2026 · quarter ended Sep 2026
Interest expense growth accelerates
Q3 FY2026 interest expense of $358M rose 2.0% year over year, ahead of the -17.4% change in trailing-twelve-month interest expense. Sequentially, it rose 539.3% from the prior quarter. Over 3 fiscal years it compounded at +18.1% a year.
Context
- Interest expense amounted to 0.7% of revenue in FY2025, unchanged from a year earlier.
- Interest expense increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +2.0% holds above the trailing-twelve-month pace of -17.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 1.4B USD
- Year-over-year change
- +18.3%
- 4-year CAGR
- +15.1%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.4B | +18.3% |
| FY2024 | 2024-12-31 | 1.19B | +15.0% |
| FY2023 | 2023-12-31 | 1.03B | +21.0% |
| FY2022 | 2022-12-31 | 851M | +6.6% |
| FY2021 | 2021-12-31 | 798M | — |
Interest Expense vs competitors
How ELV compares with its peers on the latest reported figures
- ELV's LTM Sep 2026 interest expense of $1.14B is the 4th highest of the 9 companies compared; the peer median is $704M.
- Its year-over-year change of -17.4% is the 7th highest of 9, against a peer median of -3.2%.
- Interest expense amounts to 0.6% of revenue for ELV, versus a peer median of 0.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $3.85B | -4.4% | +24.1% | 0.9% | |
| LTM Jun 2026 | $3.1B | +1.4% | +10.9% | 0.7% | |
| LTM Sep 2026 | $1.38B | -1.9% | +4.0% | 0.5% | |
| LTM Sep 2026 | $1.14B | -17.4% | +18.1% | 0.6% | |
| LTM Sep 2026 | $753M | +16.0% | +16.3% | 0.5% | |
| LTM Jun 2026 | $655M | -4.8% | +0.6% | 0.3% | |
| LTM Sep 2026 | $213M | +22.4% | +20.4% | 0.5% | |
| LTM Mar 2026 | $15.91M | -27.9% | -4.8% | 0.4% | |
| LTM Jun 2026 | $15.85M | -33.1% | -8.0% | 0.1% | |
| Peer median (excluding ELV) | $704M | -3.2% | +7.4% | 0.5% | |
Competitors are the stored peer set for ELV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 138.64B | 156.6B | 171.34B | 176.81B | 199.13B |
| Cost of Revenue | 102.65B | 116.64B | 124.33B | 127.57B | 148.22B |
| Gross Profit | 35.99B | 39.95B | 47.01B | 49.24B | 50.9B |
| Gross Margin | 26.0% | 25.5% | 27.4% | 27.9% | 25.6% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 27.05B | 31.5B | 38.27B | 40.36B | 42.79B |
| Depreciation & Amortization | 1.3B | 1.68B | 1.75B | 1.39B | 1.55B |
| EBITDA | 10.03B | 10.13B | 10.49B | 10.48B | 9.66B |
| EBITDA Margin | 7.2% | 6.5% | 6.1% | 5.9% | 4.9% |
| Operating Income | 8.95B | 8.45B | 8.75B | 8.89B | 8.11B |
| Operating Margin | 6.5% | 5.4% | 5.1% | 5.0% | 4.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 798M | 851M | 1.03B | 1.19B | 1.4B |
| Other Income / Expenses | (1.02B) | (851M) | (1.03B) | (984M) | (1.4B) |
| Income Before Tax | 7.93B | 7.6B | 7.72B | 7.9B | 6.71B |
| Pre-Tax Margin | 5.7% | 4.9% | 4.5% | 4.5% | 3.4% |
| Income Tax Expense | 1.83B | 1.71B | 1.72B | 1.93B | 1.05B |
| Net Income | 6.1B | 5.89B | 5.99B | 5.98B | 5.66B |
| Net Margin | 4.4% | 3.8% | 3.5% | 3.4% | 2.8% |
| EPS (Basic) | 25.25 | 24.56 | 25.38 | 25.81 | 25.18 |
| EPS (Diluted) | 24.73 | 24.28 | 25.22 | 25.68 | 25.12 |
| Weighted Avg Shares | 243.8M | 240M | 233.07M | 232.87M | 221.8M |
| Weighted Avg Shares (Diluted) | 246.8M | 242.8M | 237.4M | 232.9M | 221.8M |
Elevance Health Inc.
NYSE:ELV
Intrinsic Alpha fair value
Locked
Current Price
$400.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.